Liver and Pancreas Transplant and Hepatobiliary Surgery Unit, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos 2350, 6th Floor, Room 600, Porto Alegre, 90035-903, Brazil.
Division of Gastroenterology and Hepatology, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Dig Dis Sci. 2019 Jun;64(6):1695-1704. doi: 10.1007/s10620-019-5456-6. Epub 2019 Jan 14.
Although MELD score is a reliable tool for estimating mortality in the waiting list, criteria for preoperative prediction of survival after liver transplantation (LT) are lacking. ALBI score was validated as a prognostic marker for hepatocellular carcinoma patients undergoing transarterial chemoembolization, hepatic resection, and sorafenib treatment but not for LT outcomes yet. This study aimed to evaluate ALBI score as a prognostic factor in LT.
This is a single-center analysis of patients undergoing LT between October 2001 and June 2017. Primary endpoint was overall post-LT mortality. Secondary endpoint was 90-day mortality.
Of all 301 patients included in this study, 185 (61.5%) were males. The median age was 54.1 ± 11.3 years. Univariate and multivariate analysis revealed that ALBI grade 3 (HR 1.836, 95% CI 1.154-2.921, p = 0.010), low serum albumin (HR 0.628, 95% CI 0.441-0.893, p = 0.010), black race (HR 2.431, 95% CI 1.160-5.092, p = 0.019), and elevated body mass index (HR 1.061, 95% CI 1.022-1.102, p = 0.002) all were associated with decreased overall survival following LT. Patients with both ALBI grade 3 (n = 25) and calculated MELD score ≥ 25 had the lowest overall survival (p < 0.001).
ALBI grade 3 was related to lower post-LT survival and can be utilized as a tool for risk stratification in LT.
虽然 MELD 评分是评估等待名单中死亡率的可靠工具,但缺乏预测肝移植(LT)后生存率的术前标准。ALBI 评分已被验证为接受经动脉化疗栓塞、肝切除术和索拉非尼治疗的肝细胞癌患者的预后标志物,但尚未用于 LT 结果。本研究旨在评估 ALBI 评分作为 LT 的预后因素。
这是一项对 2001 年 10 月至 2017 年 6 月期间接受 LT 的患者进行的单中心分析。主要终点是 LT 后的总体死亡率。次要终点是 90 天死亡率。
在本研究纳入的 301 名患者中,185 名(61.5%)为男性。中位年龄为 54.1±11.3 岁。单因素和多因素分析显示,ALBI 分级 3(HR 1.836,95%CI 1.154-2.921,p=0.010)、低血清白蛋白(HR 0.628,95%CI 0.441-0.893,p=0.010)、黑种人(HR 2.431,95%CI 1.160-5.092,p=0.019)和升高的体重指数(HR 1.061,95%CI 1.022-1.102,p=0.002)均与 LT 后总体生存率降低相关。同时存在 ALBI 分级 3(n=25)和计算的 MELD 评分≥25 的患者总体生存率最低(p<0.001)。
ALBI 分级 3 与 LT 后生存率降低相关,可作为 LT 风险分层的工具。